{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:19:03Z","timestamp":1793215143037,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two-thirds of urate is excreted via the renal pathway and the remaining one-third via the extra-renal pathway, the latter mainly via the intestine in healthy individuals. ABCG2, a urate exporter, is expressed in various tissues including the kidney and intestine, and its dysfunction leads to hyperuricemia and gout. ABCG2 is regarded as being responsible for most of the extra-renal urate excretion. However, the extra-renal urate excretion capacity via ABCG2 remains undefined in end-stage kidney diseases. Therefore, we evaluated the capacity of extra-renal ABCG2 using 123 anuric hemodialysis patients whose urate excretion depended on only the extra-renal pathway. ABCG2 function in each participant was estimated based on <jats:italic>ABCG2<\/jats:italic> dysfunctional variants. We computed the uric acid pool (Pool<jats:sub>UA<\/jats:sub>) from bodyweight and serum urate level (SUA) using previously reported radio-isotopic data, and we analyzed the association between ABCG2 function and the Pool<jats:sub>UA<\/jats:sub>. SUA and Pool<jats:sub>UA<\/jats:sub> increased significantly with ABCG2 dysfunction, and extra-renal ABCG2 could excrete up to approximately 60% of the daily uric acid turnover in hemodialysis patients. Our findings indicate that the extra-renal urate excretion capacity can expand with renal function decline and highlight that the extra-renal pathway is particularly important in the uric acid homeostasis for patients with renal dysfunction.<\/jats:p>","DOI":"10.1038\/s41598-022-26519-x","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:10:38Z","timestamp":1673608238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients"],"prefix":"10.1038","volume":"13","author":[{"given":"Yuki","family":"Ohashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genta","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritsugu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyoshi","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"issue":"1","key":"26519_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0021-9258(18)56639-4","volume":"181","author":"JD Benedict","year":"1949","unstructured":"Benedict, J. D., Forsham, P. H. & Stetten, D. The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid. J. Biol. Chem. 181(1), 183\u2013193 (1949).","journal-title":"J. Biol. Chem."},{"issue":"8","key":"26519_CR2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1172\/JCI102343","volume":"29","author":"JD Benedict","year":"1950","unstructured":"Benedict, J. D., Forsham, P. H., Roche, M., Soloway, S. & Stetten, D. Jr. The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout. J. Clin. Invest. 29(8), 1104\u20131111 (1950).","journal-title":"J. Clin. Invest."},{"issue":"8","key":"26519_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI102504","volume":"30","author":"C Bishop","year":"1951","unstructured":"Bishop, C., Garner, W. & Talbott, J. H. Pool size, turnover rate, and rapidity of equilibration of injected isotopic uric acid in normal and pathological subjects. J. Clin. Invest. 30(8), 879\u2013888 (1951).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"26519_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0021-9258(18)55717-3","volume":"196","author":"J Buzard","year":"1952","unstructured":"Buzard, J., Bishop, C. & Talbott, J. H. Recovery in humans of intravenously injected isotopic uric acid. J. Biol. Chem. 196(1), 179\u2013184 (1952).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"26519_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0021-9258(19)52609-6","volume":"203","author":"JB Wyngaarden","year":"1953","unstructured":"Wyngaarden, J. B. & Stetten, D. Jr. Uricolysis in normal man. J. Biol. Chem. 203(1), 9\u201321 (1953).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"26519_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3181\/00379727-86-21225","volume":"86","author":"C Bishop","year":"1954","unstructured":"Bishop, C., Beyer, A. & Talbott, J. H. Isotopic uric acid in gouty and rheumatoid arthritis patients treated with probenecid and phenylbutazone. Proc. Soc. Exp. Biol. Med. 86(4), 760\u2013762 (1954).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"26519_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1172\/JCI103078","volume":"34","author":"JB Wyngaarden","year":"1955","unstructured":"Wyngaarden, J. B. The effect of phenylbutazone on uric acid metabolism in two normal subjects. J. Clin. Invest. 34(2), 256\u2013262 (1955).","journal-title":"J. Clin. Invest."},{"key":"26519_CR8","first-page":"687","volume":"8","author":"LB Sorensen","year":"1959","unstructured":"Sorensen, L. B. Degradation of uric acid in man. Metabolism 8, 687\u2013703 (1959).","journal-title":"Metabolism"},{"key":"26519_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1172\/JCI104360","volume":"40","author":"JE Seegmiller","year":"1961","unstructured":"Seegmiller, J. E., Grayzel, A. I., Laster, L. & Liddle, L. Uric acid production in gout. J. Clin. Invest. 40, 1304\u20131314 (1961).","journal-title":"J. Clin. Invest."},{"key":"26519_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archinte.1962.03620160005002","volume":"109","author":"LB Sorensen","year":"1962","unstructured":"Sorensen, L. B. The pathogenesis of gout. Arch. Intern. Med. 109, 379\u2013390 (1962).","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"26519_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0022-3476(68)80339-7","volume":"72","author":"WN Kelley","year":"1968","unstructured":"Kelley, W. N., Rosenbloom, F. M., Seegmiller, J. E. & Howell, R. R. Excessive production of uric acid in type I glycogen storage disease. J. Pediatr. 72(4), 488\u2013496 (1968).","journal-title":"J. Pediatr."},{"issue":"4","key":"26519_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/ard.28.4.366","volume":"28","author":"JT Scott","year":"1969","unstructured":"Scott, J. T., Holloway, V. P., Glass, H. I. & Arnot, R. N. Studies of uric acid pool size and turnover rate. Ann. Rheum. Dis. 28(4), 366\u2013373 (1969).","journal-title":"Ann. Rheum. Dis."},{"issue":"6887","key":"26519_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto, A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417(6887), 447\u2013452 (2002).","journal-title":"Nature"},{"issue":"4","key":"26519_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart, V. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. Genet. 40(4), 437\u2013442 (2008).","journal-title":"Nat. Genet."},{"issue":"4","key":"26519_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MNH.0000000000000427","volume":"27","author":"SK Nigam","year":"2018","unstructured":"Nigam, S. K. & Bhatnagar, V. The systems biology of uric acid transporters: The role of remote sensing and signaling. Curr. Opin. Nephrol. Hypertens. 27(4), 305\u2013313 (2018).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"6","key":"26519_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","volume":"19","author":"IA Bobulescu","year":"2012","unstructured":"Bobulescu, I. A. & Moe, O. W. Renal transport of uric acid: Evolving concepts and uncertainties. Adv. Chronic Kidney Dis. 19(6), 358\u2013371 (2012).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"26519_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","volume":"213","author":"J Maiuolo","year":"2016","unstructured":"Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C. & Mollace, V. Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 213, 8\u201314 (2016).","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"26519_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.ki.5002645","volume":"73","author":"M Huls","year":"2008","unstructured":"Huls, M. et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 73(2), 220\u2013225 (2008).","journal-title":"Kidney Int."},{"issue":"8","key":"26519_CR19","first-page":"3458","volume":"61","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard, M. et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61(8), 3458\u20133464 (2001).","journal-title":"Cancer Res."},{"issue":"5","key":"26519_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.bcp.2005.05.031","volume":"70","author":"H Gutmann","year":"2005","unstructured":"Gutmann, H., Hruz, P., Zimmermann, C., Beglinger, C. & Drewe, J. Distribution of breast cancer resistance protein (BCRP\/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70(5), 695\u2013699 (2005).","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"26519_CR21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1124\/dmd.107.014902","volume":"35","author":"C Hilgendorf","year":"2007","unstructured":"Hilgendorf, C. et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35(8), 1333\u20131340 (2007).","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"26519_CR22","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1080\/13880209.2016.1195847","volume":"54","author":"X Xu","year":"2016","unstructured":"Xu, X., Li, C., Zhou, P. & Jiang, T. Uric acid transporters hiding in the intestine. Pharm. Biol. 54(12), 3151\u20133155 (2016).","journal-title":"Pharm. Biol."},{"key":"26519_CR23","doi-asserted-by":"publisher","first-page":"43614","DOI":"10.1038\/srep43614","volume":"7","author":"Z Dong","year":"2017","unstructured":"Dong, Z. et al. Effects of multiple genetic loci on the pathogenesis from serum urate to gout. Sci. Rep. 7, 43614 (2017).","journal-title":"Sci. Rep."},{"issue":"3","key":"26519_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ckj\/sfw010","volume":"9","author":"V Bhatnagar","year":"2016","unstructured":"Bhatnagar, V. et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: Potential role of remote sensing and signaling. Clin. Kidney J. 9(3), 444\u2013453 (2016).","journal-title":"Clin. Kidney J."},{"issue":"1","key":"26519_CR25","doi-asserted-by":"publisher","first-page":"13184","DOI":"10.1038\/s41598-018-31282-z","volume":"8","author":"J Jing","year":"2018","unstructured":"Jing, J. et al. Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease. Sci. Rep. 8(1), 13184 (2018).","journal-title":"Sci. Rep."},{"key":"26519_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida, K. et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3, 764 (2012).","journal-title":"Nat. Commun."},{"issue":"2","key":"26519_CR27","doi-asserted-by":"publisher","first-page":"e30456","DOI":"10.1371\/journal.pone.0030456","volume":"7","author":"A Hosomi","year":"2012","unstructured":"Hosomi, A., Nakanishi, T., Fujita, T. & Tamai, I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP\/ABCG2. PLoS ONE 7(2), e30456 (2012).","journal-title":"PLoS ONE"},{"issue":"1","key":"26519_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10157-013-0806-8","volume":"18","author":"H Yano","year":"2014","unstructured":"Yano, H., Tamura, Y., Kobayashi, K., Tanemoto, M. & Uchida, S. Uric acid transporter ABCG2 is increased in the intestine of the 5\/6 nephrectomy rat model of chronic kidney disease. Clin. Exp. Nephrol. 18(1), 50\u201355 (2014).","journal-title":"Clin. Exp. Nephrol."},{"issue":"4\u20136","key":"26519_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/15257770.2013.854902","volume":"33","author":"T Takada","year":"2014","unstructured":"Takada, T. et al. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion. Nucleosides Nucleotides Nucleic Acids 33(4\u20136), 275\u2013281 (2014).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"26519_CR30","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1038\/srep03755","volume":"4","author":"H Matsuo","year":"2014","unstructured":"Matsuo, H. et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci. Rep. 4, 3755 (2014).","journal-title":"Sci. Rep."},{"key":"26519_CR31","doi-asserted-by":"publisher","first-page":"31003","DOI":"10.1038\/srep31003","volume":"6","author":"H Matsuo","year":"2016","unstructured":"Matsuo, H. et al. Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci. Rep. 6, 31003 (2016).","journal-title":"Sci. Rep."},{"issue":"1","key":"26519_CR32","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41467-020-16525-w","volume":"11","author":"KM Hoque","year":"2020","unstructured":"Hoque, K. M. et al. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat. Commun. 11(1), 2767 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"26519_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bmcl.2011.11.055","volume":"22","author":"K Yashio","year":"2012","unstructured":"Yashio, K. et al. Synthesis of [11C]uric acid, using [11C]phosgene, as a possible biomarker in PET imaging for diagnosis of gout. Bioorg. Med. Chem. Lett. 22(1), 115\u2013119 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"26","key":"26519_CR34","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJM197906283002604","volume":"300","author":"GR Boss","year":"1979","unstructured":"Boss, G. R. & Seegmiller, J. E. Hyperuricemia and gout. Classification, complications and management. N. Engl. J. Med. 300(26), 1459\u20131468 (1979).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"26519_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/15257770.2010.494651","volume":"29","author":"M Hosoyamada","year":"2010","unstructured":"Hosoyamada, M., Takiue, Y., Shibasaki, T. & Saito, H. The effect of testosterone upon the urate reabsorptive transport system in mouse kidney. Nucleosides Nucleotides Nucleic Acids 29(7), 574\u2013579 (2010).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"8","key":"26519_CR36","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","volume":"13","author":"E Miyauchi","year":"2016","unstructured":"Miyauchi, E. et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol. Pharm. 13(8), 2631\u20132640 (2016).","journal-title":"Mol. Pharm."},{"issue":"6","key":"26519_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/clpt.1991.205","volume":"50","author":"R Guerciolini","year":"1991","unstructured":"Guerciolini, R., Szumlanski, C. & Weinshilboum, R. M. Human liver xanthine oxidase: Nature and extent of individual variation. Clin. Pharmacol. Ther. 50(6), 663\u2013672 (1991).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"26519_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/acs.molpharmaceut.9b01060","volume":"17","author":"I Hernandez Lozano","year":"2020","unstructured":"Hernandez Lozano, I. et al. Measurement of hepatic ABCB1 and ABCG2 transport activity with [(11)C] Tariquidar and PET in humans and mice. Mol. Pharm. 17(1), 316\u2013326 (2020).","journal-title":"Mol. Pharm."},{"issue":"5","key":"26519_CR39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/trf.13515","volume":"56","author":"S Fujita","year":"2016","unstructured":"Fujita, S. et al. Expression levels of ABCG2 on cord red blood cells and study of fetal anemia associated with anti-Jr(a). Transfusion 56(5), 1171\u20131181 (2016).","journal-title":"Transfusion"},{"issue":"3","key":"26519_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.kint.2016.09.041","volume":"91","author":"R Sugimoto","year":"2017","unstructured":"Sugimoto, R. et al. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 91(3), 658\u2013670 (2017).","journal-title":"Kidney Int."},{"key":"26519_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000237","author":"H Matsuo","year":"2009","unstructured":"Matsuo, H. et al. Common defects of ABCG2, a high-capacity urate exporter, Cause Gout: A function-based genetic analysis in a Japanese population. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.3000237 (2009).","journal-title":"Sci. Transl. Med."},{"key":"26519_CR42","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1038\/srep02014","volume":"3","author":"H Matsuo","year":"2013","unstructured":"Matsuo, H. et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci. Rep. 3, 2014 (2013).","journal-title":"Sci. Rep."},{"key":"26519_CR43","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1038\/srep05227","volume":"4","author":"A Nakayama","year":"2014","unstructured":"Nakayama, A. et al. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci. Rep. 4, 5227 (2014).","journal-title":"Sci. Rep."},{"key":"26519_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fphar.2016.00518","volume":"7","author":"H Miyata","year":"2016","unstructured":"Miyata, H. et al. Identification of febuxostat as a new strong ABCG2 inhibitor: Potential applications and risks in clinical situations. Front. Pharmacol. 7, 518 (2016).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"26519_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/annrheumdis-2019-216644","volume":"79","author":"A Nakayama","year":"2020","unstructured":"Nakayama, A. et al. Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Ann. Rheum. Dis. 79(5), 657\u2013665 (2020).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"26519_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/cells8040363","volume":"8","author":"Y Toyoda","year":"2019","unstructured":"Toyoda, Y. et al. Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. Cells 8(4), 363 (2019).","journal-title":"Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26519-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:16:16Z","timestamp":1673608576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26519-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["26519"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26519-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}